177 related articles for article (PubMed ID: 12378395)
1. [State of treatment of coronary artery disease by drug releasing stents].
Müller R; Büllesfeld L; Gerckens U; Grube E
Herz; 2002 Sep; 27(6):508-13. PubMed ID: 12378395
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting stents: clinical experiences and perspectives.
Grube E; Gerckens U; Buellesfeld L
Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting stent: the emerging technique for the prevention of restenosis.
Sheiban I; Carrieri L; Catuzzo B; Destefanis P; Oliaro E; Moretti C; Trevi GP
Minerva Cardioangiol; 2002 Oct; 50(5):443-53. PubMed ID: 12384626
[TBL] [Abstract][Full Text] [Related]
5. [Drug-eluting stents do they make the difference? ].
Presbitero P; Asioli M
Minerva Cardioangiol; 2002 Oct; 50(5):431-42. PubMed ID: 12384625
[TBL] [Abstract][Full Text] [Related]
6. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
7. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
Büllesfeld L; Gerckens U; Müller R; Grube E
Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
[TBL] [Abstract][Full Text] [Related]
8. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
9. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
10. Through the drug-eluting stent labyrinth.
Guagliumi G; Musumeci G; Vassileva A; Tespili M; Valsecchi O
Ital Heart J; 2003 Apr; 4(4):236-45. PubMed ID: 12784776
[TBL] [Abstract][Full Text] [Related]
11. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
Silber S
J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
[TBL] [Abstract][Full Text] [Related]
12. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.
Degertekin M; Regar E; Tanabe K; Lee CH; Serruys PW
Minerva Cardioangiol; 2002 Oct; 50(5):405-18. PubMed ID: 12384623
[TBL] [Abstract][Full Text] [Related]
14. Clinical evidence on polymer-based sirolimus and paclitaxel eluting stents.
Iijima R; Mehilli J; Schömig A; Kastrati A
Minerva Cardioangiol; 2006 Oct; 54(5):539-55. PubMed ID: 17019392
[TBL] [Abstract][Full Text] [Related]
15. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
[TBL] [Abstract][Full Text] [Related]
16. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
17. [When are drug-eluting stents effective? A critical analysis of the presently available data].
Silber S
Z Kardiol; 2004 Sep; 93(9):649-63. PubMed ID: 15365732
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
19. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
Ray GM; Nawarskas JJ; Frishman WH
Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
